Targeting sacubitril/valsartan for heart failure with mildly reduced or preserved ejection fraction

Letter Cardiac & Cardiovascular Systems

Adoption of Sacubitril/Valsartan Among Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction: The Get With The Guidelines-Heart Failure Registry

Jacob B. B. Pierce et al.

CIRCULATION-HEART FAILURE (2023)

Article Cardiac & Cardiovascular Systems

Sacubitril/valsartan in heart failure with mildly reduced or preserved ejection fraction: a pre-specified participant-level pooled analysis of PARAGLIDE-HF and PARAGON-HF

Muthiah Vaduganathan et al.

Summary: Pooled analyses of PARAGLIDE-HF and PARAGON-HF demonstrate that sacubitril/valsartan can significantly reduce the risk of heart failure exacerbation and cardiovascular and renal events in patients with heart failure. These data support the use of sacubitril/valsartan in patients with heart failure, particularly those with mildly reduced or preserved ejection fraction.

EUROPEAN HEART JOURNAL (2023)

添加到收藏夹

Article Medicine, General & Internal

Global Variations in Heart Failure Etiology, Management, and Outcomes

Philip Joseph et al.

Summary: This study examines the differences in heart failure (HF) etiology, treatment, and outcomes between countries with different levels of economic development. The findings highlight the importance of understanding these differences in order to improve HF prevention and treatment globally.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2023)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Angiotensin-Neprilysin Inhibition in Patients With Mildly Reduced or Preserved Ejection Fraction and Worsening Heart Failure

Robert J. Mentz et al.

Summary: In patients with EF >40% stabilized after a WHF event, sacubitril/valsartan led to a greater reduction in plasma NT-proBNP levels and was associated with clinical benefit compared with valsartan alone, despite an increased occurrence of symptomatic hypotension.

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2023)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines

Paul A. Heidenreich et al.

Summary: This article provides an overview of the 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure, including its aim, methods, and structure.

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2022)

添加到收藏夹

Article Medicine, General & Internal

Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction

S. D. Solomon et al.

Summary: The study shows that SGLT2 inhibitors are effective in reducing the risk of hospitalization for heart failure and cardiovascular death among patients with chronic heart failure and a left ventricular ejection fraction of 40% or less. However, whether they are effective in patients with a higher left ventricular ejection fraction remains uncertain.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

添加到收藏夹

Editorial Material Medicine, General & Internal

Contextualizing Risk Among Patients With Heart Failure

Stephen J. Greene et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2021)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

In-Hospital Initiation of Sodium-Glucose Cotransporter-2 Inhibitors for Heart Failure With Reduced Ejection Fraction

Vishal N. Rao et al.

Summary: SGLT-2 inhibitor therapy is well suited for initiation during heart failure hospitalization, with rapid clinical benefits and minimal risk. Delaying initiation to the outpatient setting may increase early postdischarge risks.

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2021)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure

Theresa A. McDonagh et al.

EUROPEAN HEART JOURNAL (2021)

添加到收藏夹

Article Medicine, General & Internal

Empagliflozin in Heart Failure with a Preserved Ejection Fraction

Stefan D. Anker et al.

Summary: Empagliflozin reduces the risk of cardiovascular death or hospitalization for heart failure in patients with heart failure and a preserved ejection fraction, regardless of the presence or absence of diabetes.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

添加到收藏夹

Article Medicine, General & Internal